209 related articles for article (PubMed ID: 30759785)
41. 68Ga-DOTA-NGR as a novel molecular probe for APN-positive tumor imaging using MicroPET.
Zhang J; Lu X; Wan N; Hua Z; Wang Z; Huang H; Yang M; Wang F
Nucl Med Biol; 2014 Mar; 41(3):268-75. PubMed ID: 24438818
[TBL] [Abstract][Full Text] [Related]
42. Influence of nuclides and chelators on imaging using affibody molecules: comparative evaluation of recombinant affibody molecules site-specifically labeled with ⁶⁸Ga and ¹¹¹In via maleimido derivatives of DOTA and NODAGA.
Altai M; Strand J; Rosik D; Selvaraju RK; Eriksson Karlström A; Orlova A; Tolmachev V
Bioconjug Chem; 2013 Jun; 24(6):1102-9. PubMed ID: 23705574
[TBL] [Abstract][Full Text] [Related]
43. DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours.
Zhang H; Schuhmacher J; Waser B; Wild D; Eisenhut M; Reubi JC; Maecke HR
Eur J Nucl Med Mol Imaging; 2007 Aug; 34(8):1198-208. PubMed ID: 17262215
[TBL] [Abstract][Full Text] [Related]
44. Synthesis of novel gallium-68 labeled rhodamine: A potential PET myocardial perfusion agent.
Jammaz IA; Al-Otaibi B; Al-Hokbani N; Okarvi SM
Appl Radiat Isot; 2019 Feb; 144():29-33. PubMed ID: 30508730
[TBL] [Abstract][Full Text] [Related]
45. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
[TBL] [Abstract][Full Text] [Related]
46. Preclinical evaluation of melanocortin-1 receptor (MC1-R) specific
Nagy G; Dénes N; Kis A; Szabó JP; Berényi E; Garai I; Bai P; Hajdu I; Szikra D; Trencsényi G
Eur J Pharm Sci; 2017 Aug; 106():336-344. PubMed ID: 28625749
[TBL] [Abstract][Full Text] [Related]
47. In vivo evaluation of a radiogallium-labeled bifunctional radiopharmaceutical, Ga-DOTA-MN2, for hypoxic tumor imaging.
Sano K; Okada M; Hisada H; Shimokawa K; Saji H; Maeda M; Mukai T
Biol Pharm Bull; 2013; 36(4):602-8. PubMed ID: 23546294
[TBL] [Abstract][Full Text] [Related]
48. Synthesis of 68Ga-labeled DOTA-nitroimidazole derivatives and their feasibilities as hypoxia imaging PET tracers.
Hoigebazar L; Jeong JM; Hong MK; Kim YJ; Lee JY; Shetty D; Lee YS; Lee DS; Chung JK; Lee MC
Bioorg Med Chem; 2011 Apr; 19(7):2176-81. PubMed ID: 21419635
[TBL] [Abstract][Full Text] [Related]
49. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M
J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127
[TBL] [Abstract][Full Text] [Related]
50. 68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology.
Dalm SU; Bakker IL; de Blois E; Doeswijk GN; Konijnenberg MW; Orlandi F; Barbato D; Tedesco M; Maina T; Nock BA; de Jong M
J Nucl Med; 2017 Feb; 58(2):293-299. PubMed ID: 27609789
[TBL] [Abstract][Full Text] [Related]
51. New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using 177Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts.
Persson M; Rasmussen P; Madsen J; Ploug M; Kjaer A
Nucl Med Biol; 2012 Oct; 39(7):962-9. PubMed ID: 22739362
[TBL] [Abstract][Full Text] [Related]
52. Development of new folate-based PET radiotracers: preclinical evaluation of ⁶⁸Ga-DOTA-folate conjugates.
Fani M; Wang X; Nicolas G; Medina C; Raynal I; Port M; Maecke HR
Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):108-19. PubMed ID: 20799032
[TBL] [Abstract][Full Text] [Related]
53. Matrix metalloproteinase 9 targeting peptides: syntheses, 68Ga-labeling, and preliminary evaluation in a rat melanoma xenograft model.
Ujula T; Huttunen M; Luoto P; Peräkylä H; Simpura I; Wilson I; Bergman M; Roivainen A
Bioconjug Chem; 2010 Sep; 21(9):1612-21. PubMed ID: 20795647
[TBL] [Abstract][Full Text] [Related]
54. Preclinical Study on GRPR-Targeted (68)Ga-Probes for PET Imaging of Prostate Cancer.
Sun Y; Ma X; Zhang Z; Sun Z; Loft M; Ding B; Liu C; Xu L; Yang M; Jiang Y; Liu J; Xiao Y; Cheng Z; Hong X
Bioconjug Chem; 2016 Aug; 27(8):1857-64. PubMed ID: 27399868
[TBL] [Abstract][Full Text] [Related]
55. (64)Cu- and (68)Ga-Based PET Imaging of Folate Receptor-Positive Tumors: Development and Evaluation of an Albumin-Binding NODAGA-Folate.
Farkas R; Siwowska K; Ametamey SM; Schibli R; van der Meulen NP; Müller C
Mol Pharm; 2016 Jun; 13(6):1979-87. PubMed ID: 27145400
[TBL] [Abstract][Full Text] [Related]
56. Evidence of
Marenco M; Lodola L; Persico MG; Frangipane V; Facoetti A; Aprile C; Hodolič M
Curr Pharm Biotechnol; 2018; 19(9):754-759. PubMed ID: 30160211
[TBL] [Abstract][Full Text] [Related]
57. Syntheses and evaluation of
Chakraborty S; Goswami D; Chakravarty R; Mohammed SK; Sarma HD; Dash A
Chem Biol Drug Des; 2018 Sep; 92(3):1618-1626. PubMed ID: 29729071
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of a novel radiofolate in tumour-bearing mice: promising prospects for folate-based radionuclide therapy.
Müller C; Mindt TL; de Jong M; Schibli R
Eur J Nucl Med Mol Imaging; 2009 Jun; 36(6):938-46. PubMed ID: 19183997
[TBL] [Abstract][Full Text] [Related]
59. The use of radiocobalt as a label improves imaging of EGFR using DOTA-conjugated Affibody molecule.
Garousi J; Andersson KG; Dam JH; Olsen BB; Mitran B; Orlova A; Buijs J; Ståhl S; Löfblom J; Thisgaard H; Tolmachev V
Sci Rep; 2017 Jul; 7(1):5961. PubMed ID: 28729680
[TBL] [Abstract][Full Text] [Related]
60. Toward realization of 'mix-and-use' approach in ⁶⁸Ga radiopharmacy: preparation, evaluation and preliminary clinical utilization of ⁶⁸Ga-labeled NODAGA-coupled RGD peptide derivative.
Chakraborty S; Chakravarty R; Vatsa R; Bhusari P; Sarma HD; Shukla J; Mittal BR; Dash A
Nucl Med Biol; 2016 Jan; 43(1):116-123. PubMed ID: 26527030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
